Amryt Pharma plc, a commercial stage pharmaceutical company, focuses on the acquisition, development, and commercialization of medicines for the treatment of rare and orphan diseases.
The last earnings update was 36 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Amryt Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Amryt Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Amryt Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Amryt Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Amryt Pharma has negative assets, we can't compare the value of its assets to the Europe Pharmaceuticals industry average.
Take a look at our analysis of AYP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Amryt Pharma's regulatory filings and announcements.
Unable to determine if Amryt Pharma is high growth as no earnings estimate data is available.
Amryt Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Amryt Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. Joseph Wiley, also known as Joe, M.D. is the Founder of Amryt Pharma plc and serves as its Chief Executive Officer. Dr. Wiley has over 20 years of experience in the pharmaceutical, medical and venture industries. Dr. Wiley served as a Principal of Sofinnova Ventures, Inc. Dr. Wiley joined Sofinnova Ventures in 2012 and was responsible for sourcing, evaluating and supporting the team’s investments in Ireland. He opened and led Sofinnova Ventures' European office. Dr. Wiley served as a Senior Investment Manager, Private Equity at Maven Capital Partners UK LLP and White Rose Technology Seedcorn Fund. He was employed at Inventages Venture Capital Investment Inc. He served as the Head of Healthcare and Investment Director at Synova Capital LLP, where he joined in March 2010. He served as a Medical Director at Astellas Pharma, where he focused on transplant, urology and pain. Dr. Wiley served as an Associate Director at Spirit Capital Partners LLP. He had responsibility for origination initiatives in the Midlands and a specific focus on the healthcare sector. Dr. Wiley served as a Senior Investment Manager of Private Equity at Aberdeen Asset Managers Private Equity Ltd., where he joined in February 2005. Dr. Wiley managed the White Rose Fund and was also responsible for its investments in EDSR Holdings Limited and Enpure Holdings Limited. He was responsible for investments in Celltran Limited, Syntopix Limited and Pro-Cure Therapeutics Ltd. Dr. Wiley spent at a year at Inventages Venture Capital in Geneva, where he was responsible for making early stage investments in life sciences and biotechnology companies. He worked in clinical medicine as a practicing Neurologist and has published in Neurogenetics. Dr. Wiley serves as a Director of Axordia Limited, Asterion Limted and Enpure Holdings Limited. He has been a Director at Amryt Pharma plc since April 19, 2016. He served as an Independent Director at Innocoll Holdings plc (formerly known as Innocoll AG) from March 16, 2016 to July 24, 2017. Dr. Wiley served as Member of Supervisory Board of Innocoll since December 2014 until March 16, 2016. He is a Member of the Royal College of Physicians in Ireland. Dr. Wiley is a Chief Investigator in a number of pharmaceutical clinical trials. He conducted Parkinson’s Disease research at the Mayo Clinic and was published in many scientific journals, including Neurology and Movement Disorders. Dr. Wiley graduated with an M.B.A. from INSEAD and has a Degree in Medicine specializing in Neurology from The University of Dublin, Trinity College.
Joe's compensation has increased whilst company is loss making.
Joe's remuneration is higher than average for companies of similar size in Ireland.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Amryt Pharma management team is about average.
Head of Clinical Operations
Chief Medical Officer
Chief Commercial Officer
Head of Regulatory Affairs
Head of Europe
Head of Medical Affairs
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Amryt Pharma board of directors is about average.
Amryt Pharma plc, a commercial stage pharmaceutical company, focuses on the acquisition, development, and commercialization of medicines for the treatment of rare and orphan diseases. The company operates through two segments, Commercial and Research and Development. It offers Lojuxta (lomitapide), a drug used to treat a rare life-threatening disease Homozygous Familial Hypercholesterolaemia; and a range of dermo cosmetic products under the Imlan brand. Its products in development includes AP101 (Oleogel-S10), a prescription medicine used for the treatment of partial-thickness wounds in adults, which is in Phase III clinical trial; and AP102, a somatostatin analogue peptide medicine, which is in pre-clinical stage for patients with rare neuoendocrine diseases, such as acromegaly; and AP103, a gene therapy product line. The company operates in European Economic Area, the Middle East, North Africa, Turkey, Israel, and Switzerland. Amryt Pharma plc is based in London, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.